BAGSVAERD, DENMARK--(Marketwired - May 31, 2013) -
Novo Nordisk today announced the submission to the European Medicines
Agency of the marketing authorisation application for the approval of
IDegLira, the combination product of insulin degludec (Tresiba®), the
once-daily new-generation basal insulin analogue, with an ultra-long
duration of action, and liraglutide (Victoza®), the once-daily human
GLP-1 analogue. IDegLira has been developed for the treatment of people
with type 2 diabetes.
Company announcement No 41 / 2013: http://hugin.info/2013/R/1706200/564645.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1706200]
Further information
Media:
Mike Rulis
+45 3079 3573
Email Contact
Ken Inchausti (US)
+1 609 240 2919
Email Contact
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact
Frank Daniel Mersebach
+45 4442 0604
Email Contact
Lars Borup Jacobsen
+45 3075 3479
Email Contact
Jannick Lindegaard (US)
+1 609 786 4575
Email Contact
Help employers find you! Check out all the jobs and post your resume.
